Abstract
Low functioning of the N -methyl-D-aspartate (NMDA) receptor has been hypothesized for schizophrenia. Clinical evidence for this hypothesis includes psychotic effects of phencyclidine, which acts at the NMDA receptor, and preliminary positive findings of treatment with d-serine, a co-agonist at the NMDA receptor (JW Psychiatry Sep 3 2010). In mice, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
